Condition: Advanced Solid Tumor · Sponsor: AP Biosciences Inc.
This is a Phase 1/2, multi-regional, multi-center, open-label, first-in-human (FIH), dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of AP402 in HER2-positive patients with locally or advanced solid tumors.
This description comes directly from the study's public registry record.
Linnea Shen · +886-2-2653-2886 · yashen@apbioinc.com
Always discuss trial participation with your own doctor first.
| Macquarie University Clinical Trials Unit | Macquarie, New South Wales, Australia | Not Yet Recruiting |
| Flinders Medical Centre | Bedford Park, South Australia, Australia | Not Yet Recruiting |
| Linear Clinical Research | Perth, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06669975